iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02802943 |
|
Recruitment Status :
Completed
First Posted : June 16, 2016
Last Update Posted : November 28, 2022
|
Sponsor:
University Hospital Tuebingen
Collaborators:
Robert Bosch Gesellschaft für Medizinische Forschung mbH
Klinikum Stuttgart
Marienhospital Stuttgart
Katharinenhospital Stuttgart
Information provided by (Responsible Party):
University Hospital Tuebingen
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | September 30, 2022 |
| Actual Study Completion Date : | November 18, 2022 |